23 September 2022
Recruiting Reviewer Board Members for Current Oncology
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
We are now recruiting Reviewer Board Members (RBMs) for the journal Current Oncology (ISSN: 1718-7729). If you are an active researcher in the field and are passionate about publishing cutting-edge research, do not hesitate to contact the Current Oncology Editorial Office (currentoncology@mdpi.com).
Current Oncology is an international, peer-reviewed, and open access journal that represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy to report upon and to review progress in the management of this disease. Current Oncology is indexed by Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases. The 2021 Impact Factor of Current Oncology is 3.109, and the CiteScore is 3.5.
The benefits of joining our Reviewer Board are as follows:
If you have any questions, suggestions, or recommendations, do not hesitate to let us know. We look forward to working with you.
Current Oncology Editorial Office